Skip to main content
Clinical Trials/NCT01881490
NCT01881490
Completed
Not Applicable

The ImageKids Study: Developing the Pediatric MR Enterography-based Damage Index in Crohn's Disease (pMEDIC) and the Pediatric Inflammatory Crohn's MRE Index (PICMI)

Shaare Zedek Medical Center1 site in 1 country240 target enrollmentJanuary 2013
ConditionsCrohn's Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Crohn's Disease
Sponsor
Shaare Zedek Medical Center
Enrollment
240
Locations
1
Primary Endpoint
Development of MRI-based Index
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The overall objectives of this study are to develop two indices capable of measuring intestinal damage, and, separately, inflammatory disease activity in Pediatric Crohn's disease by means of Magnetic Resonance Imaging with Enterography protocol (MRE) and pelvic MRI.

Detailed Description

The PICMI Score and the pMEDIC are aimed to be discriminative (at one point in time), evaluative (measuring damage progression over time) and predictive. The indices will be used as endpoint measures in clinical research and also in clinical practice to identify those who are at risk for rapid disease progression and surgery.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
March 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Dan Turner

Head of Pediatric Gastroenterology Unit

Shaare Zedek Medical Center

Eligibility Criteria

Inclusion Criteria

  • Children (under 18 years of age) with established diagnosis of CD involving any location by the presence of accepted clinical, radiologic, endoscopic and histologic criteria (33, 34).
  • Enrolment at the time of performing ileocolonoscopy and esophageal-gastroduodenoscopy (EGD) as part of clinical care for any reason.
  • Children will be enrolled at any phase of the disease (at diagnosis and thereafter as required clinically). In order to ensure enough subjects with intestinal damage and since damage is progressing over time, enrolment will be stratified based on disease duration. Enrolment for each stratum of disease duration will be closed after reaching the expected sample size.
  • 20% of enrolled children will be within 3 months of diagnosis.
  • 20% of children will be between 3 months and 2 years.
  • 20% will be 2.01 to 3 years
  • 40% will have disease duration over 3-years.
  • Children may be enrolled in any disease activity state (PCDAI 0-100).

Exclusion Criteria

  • Young children requiring anesthesia for lack of cooperation will be excluded (since the enteric contrast cannot be administered during the 2 hours before anesthesia and it is crucial that the contrast be given just prior the test).
  • For the first 120 children only, subjects not expected to be available for 18 month follow-up, will be excluded (the last 120 subjects may be enrolled as they are not followed longitudinally).

Outcomes

Primary Outcomes

Development of MRI-based Index

Time Frame: 3.5 years

The overall objectives of this study are to develop two indices capable of measuring intestinal damage, and, separately, inflammatory disease activity means of MRE. The indices are aimed to be discriminative, evaluative and predictive. they will be used as endpoint measures in clinical research and also in clinical practice to identify those who are at risk for rapid disease progression and surgery. The data collected will be analyzed and scored by both the radiologists and the gastroenterologists. On the basis of these scores, 2 or 3 contending versions of each index will be then subjected to head-to-head evaluation by enrolling another cohort of 120 children undergoing colonoscopy and MRE/pelvic MRI. The best version for each index will be selected according to its performance in the validity, reliability and responsiveness testing. The second group of patients will not be followed longitudinally.

Secondary Outcomes

  • Exploratory(3.5 Years)

Study Sites (1)

Loading locations...

Similar Trials